ORVANA PROVIDES UPDATE ON ITS BOLIVIAN SUBSIDIARY EMIPA

Orvana said its Bolivian subsidiary EMIPA was outside the required financial covenant thresholds as of September 30, 2026, and is in a cure period through December 8, with an extension possible subject to bondholder approval. EMIPA is targeting plant throughput of approximately 1,400 tonnes per day in November, from more than 900 tonnes per day in the last week of October, and may evaluate increases toward the 1,700-tonne-per-day design rate in December. EMIPA Bonds I is scheduled to mature November 7 with its fifth and final coupon payment; Orvana cautioned that covenant compliance may not be restored within the cure period.

Analysis

The key issue is a mismatch in timing: Don Mario’s operating improvement may support future cash generation, but a throughput ramp is not yet evidence that EMIPA can cure covenant breaches on schedule. Higher rates still need to translate into stable recoveries, saleable output, and cash collection; filtration remains a potential bottleneck. Meanwhile, the covenant position creates a near-term financing and bargaining risk that can dominate ORV’s equity even if the plant performs better. The November 7 Bonds I payment, if made, removes that scheduled debt-service obligation but does not itself resolve the broader covenant breach or the February 2027 Bonds II maturity.

For the next several weeks, bondholder cooperation, cure-period terms, and the audited FY2026 accounts are more decisive than management’s design-rate targets. Over 1–3 months, the key test is whether sustained throughput and cash conversion improve covenant calculations, not whether the plant briefly reaches a target. A further Bolivia FX-regime change or renewed transport disruption could weaken the recovery; conversely, verified production and a credible, accepted remediation plan could reduce the risk discount. The exchange-rate accounting effect may also make reported leverage less informative about operating progress, so investors should separate Bolivian-GAAP subsidiary covenant measures from consolidated IFRS results. The release gives no basis to quantify EMIPA’s contribution to consolidated value or the financing shortfall, so an aggressive directional ORV trade is not justified yet.

Key Decisions for Investors

• Avoid adding to ORV ahead of the November 7 payment confirmation and late-November audited FY2026 results; treat both as near-term event risks rather than assuming the operating update resolves credit concerns.
• For existing exposure, keep sizing conservative and reassess after verifying the Bonds I payment, the exact covenant shortfalls, EMIPA’s cash and debt schedule, and whether bondholders accept a cure plan or extension. Escalate concern if the cure period approaches December 8 without an agreed path.
• Use the November–December ramp as a verification trigger, not a valuation input: look for sustained throughput, recoveries, and cash generation as rates rise toward guidance. Failure to stabilize filtration or a guidance setback would undermine the operational offset to credit risk.
• Before considering a bullish ORV position, reconcile EMIPA’s Bolivian-GAAP covenant calculations with Orvana’s consolidated IFRS statements and determine the subsidiary’s materiality to group liquidity; absent that information, there may be no attractive risk-adjusted trade.